Literature DB >> 19190805

Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure.

Ralf A Claus1, Clemens L Bockmeyer, Ulrich Budde, Karim Kentouche, Maik Sossdorf, Thomas Hilberg, Reinhart Schneppenheim, Konrad Reinhart, Michael Bauer, Frank M Brunkhorst, Wolfgang Lösche.   

Abstract

Von Willebrand factor (VWF) and related parameters as well as the protease activity regulating its biological activity were measured in plasma of healthy controls and patients with different cause and severity of systemic inflammation to examine the efficacy of the measures to detect highly prothrombotic states including thrombotic microangiopathy (TMA), one of the sequelae of sepsis. Plasma levels of VWF increased with increasing severity of systemic inflammation, probably due to activation of the endothelium. In parallel, the proteolytic activity of VWF inactivating protease, ADAMTS13, stepwise declined with the severity of inflammation, emphasizing the role of VWF-triggered platelet aggregation on the endothelium subsequently followed by development of TMA. As a consequence, the ratio of VWF antigen level and ADAMTS13 activity was significantly higher in patients with inflammation and sepsis, suggesting that this ratio might be more useful for the diagnosis of highly prothrombotic states including TMA than VWF multimer analysis alone. These findings suggest that ADAMTS13, VWF and related parameters, even in a combined approach, might be useful for the diagnosis and the therapeutic monitoring of patients with sepsis associated thrombotic microangiopathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190805

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  34 in total

1.  von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.

Authors:  Alexander T Bauer; Jan Suckau; Kathrin Frank; Anna Desch; Lukas Goertz; Andreas H Wagner; Markus Hecker; Tobias Goerge; Ludmila Umansky; Philipp Beckhove; Jochen Utikal; Christian Gorzelanny; Nancy Diaz-Valdes; Viktor Umansky; Stefan W Schneider
Journal:  Blood       Date:  2015-02-24       Impact factor: 22.113

2.  Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure.

Authors:  K S Prasanna; Ashish Goel; G Jayakumar Amirtharaj; Anup Ramachandran; K A Balasubramanian; Ian Mackie; Uday Zachariah; K G Sajith; Elwyn Elias; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2016-11-08

3.  Endothelial Permeability and Hemostasis in Septic Shock: Results From the ProCESS Trial.

Authors:  Peter C Hou; Michael R Filbin; Henry Wang; Long Ngo; David T Huang; William C Aird; Donald M Yealy; Derek C Angus; John A Kellum; Nathan I Shapiro
Journal:  Chest       Date:  2017-01-19       Impact factor: 9.410

4.  Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C.

Authors:  Michael L Ekaney; Clemens L Bockmeyer; Maik Sossdorf; Philipp A Reuken; Florian Conradi; Tobias Schuerholz; Markus F Blaess; Scott L Friedman; Wolfgang Lösche; Michael Bauer; Ralf A Claus
Journal:  Mol Med       Date:  2015-04-03       Impact factor: 6.354

5.  Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.

Authors:  Renyong Guo; Jiezuan Yang; Xia Liu; Jianping Wu; Yu Chen
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

6.  The ABO histo-blood group, endothelial activation, and acute respiratory distress syndrome risk in critical illness.

Authors:  John P Reilly; Nuala J Meyer; Michael Gs Shashaty; Brian J Anderson; Caroline Ittner; Thomas G Dunn; Brian Lim; Caitlin Forker; Michael P Bonk; Ethan Kotloff; Rui Feng; Edward Cantu; Nilam S Mangalmurti; Carolyn S Calfee; Michael A Matthay; Carmen Mikacenic; Keith R Walley; James Russell; David C Christiani; Mark M Wurfel; Paul N Lanken; Muredach P Reilly; Jason D Christie
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

7.  Von Willebrand factor, ADAMTS13 activity, TNF-α and their relationships in patients with chronic kidney disease.

Authors:  Lei Shen; Guoyuan Lu; Ningzheng Dong; Liqiong Jiang; Zhenni Ma; Changgeng Ruan
Journal:  Exp Ther Med       Date:  2011-12-23       Impact factor: 2.447

8.  Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of splenectomy: the significance of ADAMTS13 and graft function [corrected].

Authors:  Yu Nobuoka; Hideo Wada; Shugo Mizuno; Masashi Kishiwada; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata; Toshihiko Kobayashi; Tsutomu Nobori; Shinji Uemoto; Shuji Isaji
Journal:  Int J Hematol       Date:  2014-03-05       Impact factor: 2.490

9.  The ABO Histo-Blood Group and AKI in Critically Ill Patients with Trauma or Sepsis.

Authors:  John P Reilly; Brian J Anderson; Nilam S Mangalmurti; Tam D Nguyen; Daniel N Holena; Qufei Wu; Ethan T Nguyen; Muredach P Reilly; Paul N Lanken; Jason D Christie; Nuala J Meyer; Michael G S Shashaty
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-04       Impact factor: 8.237

Review 10.  VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.

Authors:  Michael Schwameis; Christian Schörgenhofer; Alice Assinger; Margarete M Steiner; Bernd Jilma
Journal:  Thromb Haemost       Date:  2014-12-11       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.